louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01731756: Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis
Official title: Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis: Randomized, Double Blind, Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arsenical Keratosis
Keywords: Palm
Arsenic
Keratosis
Salicylic acid
Azadirachta indica
Neem
Lead sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Sponsor class: OTHER
First posted: 2012-11-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Effects of leaf extract of Azadirachta indica in palmer arsenical keratosis: Randomized, double-blind, placebo-control trial

Detailed description: The objective of this study is to evaluate the effectiveness of topical administration of the Leaf of Azadirachta indica in the treatment of palmer arsenical keratosis. Fifty patients of moderate palmer arsenical keratosis patients from an arsenic affected area will be recruited on the basis of inclusion and exclusion criteria and had been drinking arsenic contaminated water for more than six months. They will be divided into two groups each will consist of twenty five members. One group will be provided A. indica plus 6% salicylic acid ointment to apply on palm overnight daily for 12 weeks. Another group will be provided 6% salicylic acid ointment . Water and nail sample will be collected before starting recruitment to confirm diagnosis. Then again nail sample will be collected before and after the study to see the level of arsenic in skin. Effects will be observed after every two weeks and change will be detected as nil, mild reduction, moderate reduction and fully cured.

Eligibility criteria: Inclusion Criteria:

* Palmer arsenical keratosis
* Drinking arsenic contaminated water (\>50 ppb) for more than six months
* Patient voluntarily agree to participate

Exclusion Criteria:

* Pregnancy
* Lactating mother
* Diabetes mellitus
* Rheumatoid arthritis
* Systemic lupus erythematosus
* Psoriasis
* Bowen's disease

Primary outcomes:
measure: Changes in palmer arsenical keratosis
timeFrame: 0 week (baseline), 12 weeks (end)
Secondary outcomes:
measure: Changes in arsenic level in nail
timeFrame: 0 week (baseline), 12 weeks (end)
Other outcomes:
Locations:
city: Dhaka
country: Bangladesh
facility: Department of Pharmacology, Bangabandhu Sheikh Mujib Medical University
Study officials:
affiliation: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
name: Mir Misbahuddin, MBBS, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00277056: Dysregulated Tyrosine Kinase Signaling in Leukemia
Official title: Dysregulated Tyrosine Kinase Signaling in Leukemia
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Leukemia
Keywords: leukemia
Lead sponsor: University of New Mexico
Sponsor class: OTHER
First posted: 2006-01-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: people with leukemia

Brief summary: Dysregulated Tyrosine Kinase Signaling in Leukemia

Detailed description: Purpose: to look at a number of proteins in the abnormal cells in the blood and/or bone marrow. These proteins make a cell grow or prevent the cell from dying

Eligibility criteria: Inclusion Criteria:

* Patients must have newly diagnosed or relapsed leukemia.
* Patients must sign an informed consent.
* Patients will not be excluded if they are receiving chemotherapy.
* Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible.
* Patients must be =\> 18 years of age.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Albuquerque
country: United States
facility: University of New Mexico
state: New Mexico
Study officials:
affiliation: University of New Mexico
name: Ian Rabinowitz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01031056: Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
Official title: Collection of Biospecimen and Clinical Information in Patients With Gastrointestinal Cancers
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Gastrointestinal Neoplasms
Gynecologic Cancers
Gynecologic Cancers Cervical Cancer
Gastric (Stomach) Cancer
Gastro-Esophageal(GE) Junction Cancer
Gastrointenstinal Stromal Tumor (GIST)
Colon/Rectal Cancer
Colon/Rectal Cancer Colon Cancer
Colon/Rectal Cancer Rectal Cancer
Colon/Rectal Cancer Anal Cancer
Anal Cancer
Hepatobiliary Cancers
Hepatobiliary Cancers Liver
Pancreatic Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: Caring for Carcinoid Foundation
name: GI Cancer Research Gift Fund
First posted: 2009-12-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with gastrointestinal cancer.

Brief summary: We have an active research program in gastrointestinal cancers including clinical trials, epidemiologic, and translational studies. We would like to establish a biospecimen bank linked to useful clinical information in order to learn more about diagnostic, predictive and prognostic markers for gastrointestinal cancers.

PRIMARY OBJECTIVES:

1. To collect and store tumor and normal tissue (previously collected paraffin embedded or frozen specimen) and blood in patients with gastrointestinal (GI) cancers.

SECONDARY OBJECTIVES:

1. Collect detailed clinical information via a patient questionnaire that includes demographic, socioeconomic, lifestyle, family, past medical, medication and cancer histories
2. Collect details about the tumor specimen extracted from patient charts.


Eligibility criteria: Inclusion Criteria:1. Patients are eligible if they have a histologically proven gastrointestinal cancer (esophageal, gastroesophageal junction, gastric, small intestine, appendix, colon, rectum, anus, liver, gallbladder, bile ducts, pancreas, neuroendocrine, and GI stromal tumor).

2. 18 years of age or older

3. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:None

Primary outcomes:
measure: None: Biospecimen will be collected for future research.
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Teri A Longacre M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06678256: A Study of Pregnancy Outcomes in Congenital Heart Disease
Official title: Pregnancy Outcomes in Patients With Adult Congenital Heart Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Congenital Heart Disease
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2024-11-07
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adults (18+) who are currently pregnant

Brief summary: The purpose of this study is to determine if a biomarker assay obtained peripartum (1st-3rd trimester and post-partum) in patients with adult congenital heart disease can predict future risk of cardiovascular adverse events and determine if temporal changes in biomarkers levels throughout the peripartum period can provide a better risk prediction compared to samples taken at a single time-point.


Eligibility criteria: Inclusion Criteria:

* Congenital Heart Disease Diagnosis
* Currently Pregnant

Exclusion Criteria:

* Unable to consent

Primary outcomes:
measure: Number of Subjects with cardiovascular adverse events
timeFrame: Baseline
Secondary outcomes:
measure: Number of Subject Deaths
timeFrame: Baseline
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Alexander Egbe, MBBS, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05878756: Effects of Additional Functional Strength Training on Mobility in Children With Hemiplegic Cerebral Palsy
Official title: Effects of Additional Functional Strength Training on Mobility in Children With Hemiplegic Cerebral Palsy,A Randomized Control Trail
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hemiplegic Cerebral Palsy
Mobility
Keywords: Cerebral palsy
Functional strength training
Mobility
GMFC
GMFM
Lead sponsor: Health Education Research Foundation (HERF)
Sponsor class: OTHER
First posted: 2023-05-26
Enrollment: 32
Sex: ALL
Minimum age (years): 4
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The randomized control trail was to determine the effects of additional functional Strength Training on mobility in Children with Hemiplegic Cerebral Palsy.

Detailed description: The aim of functional physiotherapy is to train the child by emphasizing him to learn motor abilities. These motor abilities are those that are thought to be though either by children with cerebral palsy or their parents. Functional activities are learned by the repetitive practice of goal-oriented tasks in a given functional situation. This approach instead of focusing on normality, it focuses on functionality. In this way, it is very necessary for the child to practice a given task functionally rather than normally.No studies have been done to improve mobility and strength in lower limb in children with hemiplegia cerebral palsy. So for this reason, this study is conducted to investigate the effects of additional functional Strength Training on mobility in Children with Hemiplegic Cerebral Palsy.In this way we can make these children an active participant of the society.

Eligibility criteria: Inclusion Criteria:

children who didnot use the assistive device children who follow the commands children who did not treated in any other rehabilitation center

Exclusion Criteria:

children with any other diagnosis other than CP children with fixed contractures children underwent surgery children who received Botulinum Toxin

Primary outcomes:
measure: Gross Motor Function Measure (GMFM)
timeFrame: Data was collected at Baseline and after 4 weeks
measure: Gross Motor Function Classification System (GMFCS)
timeFrame: Data was collected at Baseline and after 4 weeks
Secondary outcomes:
measure: Five time sit to stand (FTSST).
timeFrame: Data was collected at Baseline and after 4 weeks
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Yusra Institute of Rehablitation Science
Study officials:
References:
Clinical trial NCT03169556: Comparison of Conventional Lightwand Intubation Versus Video-laryngoscope Guided Lightwand Intubation in Simulated Cervical Spine-immobilized Patients
Official title: Comparison of Conventional Lightwand Intubation Versus Video-laryngoscope Guided Lightwand Intubation in Simulated Cervical Spine-immobilized Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: General Anesthesia
Keywords: Intubation
light wand
video laryngoscopy
cervical spine immobilization
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2017-05-30
Enrollment: 318
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Among advanced intubation equipment for difficult intubation, a lighted stylet (lightwand) is a widely used equipment in cervical immobilized patients. However, a lightwand, which is used blind, is difficult to make midline positioning and can increase airway complications and hemodynamic changes. In contrast, videolaryngoscope can view vocal cord indirectly through camera, however, it requires cervical movement. Therefore, investigator hypothesized that the combined use of video-laryngoscope and lightwand for intubation can improve the efficacy of intubation compared to the use of lightwand alone in cervical immobilized patients.


Eligibility criteria: Inclusion Criteria:

1. Aged between 20- 80 yrs
2. Patients scheduled surgery under the general anesthesia

Exclusion Criteria:

1. Patient who has history of gastro-esophageal reflux disease, previous airway surgery, anatomical abnormality in the upper airway, or coagulopathy
2. Patients with body mass index \>35kg/m2, hemodynamic instability or loosening teeth
3. Patient who disagrees to participate this study or lacks decision-making ability, illiteracy, or foreigner
4. American Society of Anesthesiologists physical status ≥ 3

Primary outcomes:
measure: The success rate of intubation
timeFrame: Within 90 sec after insertion of lightwand or video-laryngosocpe into oral cavity.
measure: The duration of intubation
timeFrame: Within 90 sec after insertion of lightwand or video-laryngosocpe into oral cavity.
Secondary outcomes:
measure: number of intubation trial and scooping movements
timeFrame: during intubation time, intubation attempts allows maximum 3 times, within 90 sec in each time
measure: Blood pressure change
timeFrame: from start of intubation to 5minute after intubation
measure: Injuries of oral cavity
timeFrame: at immediate after intubation and extubation
measure: Postoperative hoarseness
timeFrame: at 1hr after PACU arrival and 24hr after operation
measure: Postoperative sore throat
timeFrame: at 1hr after PACU arrival and 24hr after operation
measure: Heart rate change
timeFrame: from start of intubation to 5minute after intubation
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine
Study officials:
References:
Clinical trial NCT00725556: The Development of Autistic Children Based on Mothers´Response in Autism Behavior Checklist
Official title: The Development of Autistic Children Based on Mother´s Response in Autism Behavior Checklist
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Autism
Asperger Syndrome
Keywords: Autism
Asperger Syndrome
Lead sponsor: Federal University of São Paulo
Sponsor class: OTHER
First posted: 2008-07-30
Enrollment: 11
Sex: ALL
Minimum age (years): 3
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the process of development of autistic children, in a direct and indirect intervention context from mother´s response in Autism Behavior Checklist.

Detailed description: Aim: We evaluated the process of development of autistic children, in a direct and indirect intervention context from mother´s response in Autism Behavior Checklist.

Method:

The sample were composed of 11 mothers of children diagnosed with Autism (6) and Asperger Syndrome (5), according to the criteria established by the DSM IVtr (APA, 2002). These children were randomly divided into two groups: Six were receiving both direct and indirect intervention (Therapy Group -TG), and five were receiving exclusively indirect intervention (Orientation Group - OG). We used the Autism Behavior Checklist (Krug et al., 1993), adapted to Portuguese on three occasions: at the beginning, six months later and 12 months later. This is a list of nonadaptive behaviors (57), in the areas: Sensorial, Body and Object Use, Language, Social and Relating.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Autism or Asperger Syndrome
* Age (children)
* Adherence in the study (at least 70%)

Exclusion Criteria:

* Others clinical diagnosis

Primary outcomes:
measure: To evaluate the process of development of autistic children, in a direct and indirect intervention context from mother´s response in Autism Behavior Checklist.
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Ana Carina Tamanaha
Study officials:
affiliation: Federal University of São Paulo
name: Ana Carina Tamanaha, Student
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00798356: Yoga on Arrhythmia Burden and Quality of Life in Paroxysmal Atrial Fibrillation
Official title: The Effect of Yoga on Arrhythmia Burden and Quality of Life in Patients With Paroxysmal Atrial Fibrillation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atrial Fibrillation
Keywords: atrial fibrillation, yoga
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
First posted: 2008-11-26
Enrollment: 84
Sex: ALL
Minimum age (years): 25
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: Studies in the past have shown that yoga could relieve stress which is the most common trigger for recurrent episodes of atrial fibrillation. Breathing exercises in yoga are found to influence the autonomic nervous system (particularly parasympathetic) and thus reduce palpitations. This study hypothesizes that patients with atrial fibrillation might benefit by practicing yoga. Yoga may also help to better control heart rate and rhythm when used in combination with usual medical management.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with paroxysmal atrial fibrillation ages 25-80

Exclusion Criteria:

* Advanced malignancy or severe co-morbid conditions such as severe heart failure and with life expectancy less than 1 year
* Pregnant women
* Unmedicated or uncontrolled high blood pressure
* A past history of pneumothorax
* Severe cervical spondylitis and cervical, thoracic or lumbar disc prolapse
* Carotid stenosis
* History of psychosis or substance abuse
* History of epilepsy
* Glaucoma
* History of total hip replacement
* Ablation within 3 months of the start date of study
* Patients who have not seen a cardiovascular physician in the last year

Primary outcomes:
measure: frequency and duration of atrial fibrillation episodes
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Kansas
Study officials:
References:
citation: Lakkireddy D, Atkins D, Pillarisetti J, Ryschon K, Bommana S, Drisko J, Vanga S, Dawn B. Effect of yoga on arrhythmia burden, anxiety, depression, and quality of life in paroxysmal atrial fibrillation: the YOGA My Heart Study. J Am Coll Cardiol. 2013 Mar 19;61(11):1177-82. doi: 10.1016/j.jacc.2012.11.060. Epub 2013 Jan 30.
Clinical trial NCT02444637: Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
Official title: Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Alzheimer Disease
CVA (Cerebrovascular Accident)
Lead sponsor: National Neuroscience Institute
Sponsor class: OTHER
First posted: 2015-05-14
Enrollment: 100
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA \& HSA, is authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type.

In this trial, the investigators will be studying the effectiveness of Rivastigmine in subjects with AD and cerebrovascular disease.


Eligibility criteria: Inclusion Criteria:

* Age between 50-85 years
* Diagnosis of dementia of the Alzheimer's type according to the National Institute of Ageing-Alzheimer's Association Criteriah
* MRI brain (with T2 or FLAIR sequences) performed within a 12 month period from time of recruitment demonstrating the presence of WMH of ≥2 on the Fazekas scale (Score range of 0-3 wherein a score of 1 indicates mild WMH, 2 indicates moderate WMH and 3 indicates severe WMH).i
* Clinical Dementia Rating score of 1-2j
* Mini-Mental State Examination (MMSE) scores of 12-26 inclusivek
* English or Mandarin speaking, literate participants

Exclusion Criteria:

* Severe neurological, psychiatric or systemic disease which in the opinion of the clinician could interfere with trial assessments
* The use of any investigational drugs, new psychotropic or dopaminergic agents, cholinesterase inhibitors or anti-cholinergic agents during the 4 weeks prior to recruitment
* Known skin allergy or previous allergic reaction to Rivastigmine patch

Primary outcomes:
measure: Number of Participants with Demonstrated Benefit in Global and Cognitive Measures
timeFrame: 2 Years
Secondary outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: 2 Years
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: National Neuroscience Institute
Study officials:
References:
Clinical trial NCT06803537: Three-Year Clinical Performance of Fiber-reinforced Versus Indirect Resin Composite Posterior Restorations
Official title: Three-Year Clinical Performance of Fiber-reinforced Versus Indirect Resin Composite Posterior Restorations
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Occlusal Caries
Proximal Caries
Keywords: fiber-reinforced composite
indirect lab composite
posterior restorations
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2025-01-31
Enrollment: 33
Sex: ALL
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aimed to perform a comparison between the clinical performance of short fiber-reinforced composite and indirect lab composite restorations in posterior dentition.


Eligibility criteria: Inclusion Criteria:

1. Patients aged 20-35 year from both genders.
2. Good oral hygiene: patients with low and moderate caries risk (according to Caries management by caries risk assessment CAMBRA sheets) were enrolled in this study.
3. The visual examination should reveal the presence of a minimum of three primary occlusal or proximal caries (Black Class I and II) with a severity score of 4 or 5 according to the International Caries Detection and Assessment System (ICDAS).
4. The carious teeth must exhibit vitality and do not display periapical radiolucency as evaluated by periapical radiography.
5. The selected teeth must be under stable occlusion.

Exclusion Criteria:

1. Uncontrolled systemic disease
2. Extremely poor oral hygiene
3. Chronic periodontitis
4. Heavy bruxism
5. Cavities with a buccolingual width exceeding two-thirds of the intercuspal distance or requiring cusp covering.
6. Patients undergoing orthodontic procedures.
7. Patients unable to attend the scheduled recall appointments.

Primary outcomes:
measure: FDI criteria for evaluation
timeFrame: Three years follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Mansoura university
state: Dakahlia
Study officials:
References: